Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1989-10-12
1991-12-31
Ford, John M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544353, 564305, C07D40312, A61K 31495
Patent
active
050772929
ABSTRACT:
A compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals containing 1 to 4 carbon atoms, R.sub.2 and R.sub.3 are independently selected from the group consisting of H, OXO, and alkyl radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the qunioxaline nucleus and is selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as alteration in the rate of fluid transport in the gastrointestinal tract, reduction in intraocular pressure, and increase in renal fluid flow.
REFERENCES:
patent: 3890319 (1975-07-01), Danielewicz et al.
Gellai et al., Renal Effects of Selective Alpha-1 and Alpha-2 Adrenoceptor Agonists in Conscious, Normotensive Rats, J. of Pharmcol. & Experimental Therapeutics, 240, p. 723 (1987).
Fondacaro et al., Selective Alpha-2 Adrenoceptor Agonists Alter Fluid and Electrolyte Transport in Mammalian Small Intestine, J. of Pharmcol. & Experimental Therapeutics, 247, p. 481 (1988).
Burke et al., Ocular effects of a relatively selective Alpha-2 agonist (UK-14, 304-18) in cats, rabbits and monkeys, Current Eye Research, 5, p. 665 (1986).
Jumblatt et al., Alpha-2 adrenergic modulation of norepinephrine secretion in the perfused rabbit iris-ciliary body, Current Eye Research, 6, p. 767 (1987).
Mittag, PhD., Ocular Effects of Selective Alpha-Adrenergic Agents: A New Drug Paradox?, Annals of Ophthalmology, p. 201, (Mar., 1983).
Gellai et al., Mechanism of Alpha-2-adrenoceptor agonist-induced diuresis, Am. J. Physiol., p. F317 (1988).
Timmermans et al., Clonidine and some bridge analogues; cardiovascular effects and nuclear magnetic resonance data (H/C), Eur. J. Med. Chem., 15, p. 323 (1980).
Isom et al., Alpha-2-Adrenergic Receptors Accelerate Na/H Exchange in Neuroblastoma X Glioma Cells, J. Biol. Chem., 262, p. 6750 (1987).
Fielding et al., Clonidine: New Research in Psychotropic Drug Pharmacology, from Medicinal Research Reviews, vol. 1, pp. 97-123 (1981).
Jarrott, Clonidine and related compounds, from Handbook of Hypertension, vol. 5, p. 113 (1984).
Dharmsathaphorn, Alpha-2 Adrenergic Agonists: A Newer Class of Antidiarrheal Drug Gastroenterology 1986:91:769-775.
Allergan Inc.
Bernhardt E.
Ford John M.
Peterson Gordon L.
Uxa, Jr. Frank J.
LandOfFree
(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1510378